A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
Phase 1/2
42
about 7.4 years
18–70
3 sites in CO, NC, TN
About this study
Researchers are testing a new treatment, IOV-3001, for adults with advanced melanoma who are also receiving lifileucel. The trial will evaluate the safety and effectiveness of IOV-3001 as part of this treatment regimen.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive IOV-3001
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Safety and Tolerability
Secondary: Complete Response (CR) rate, Disease Control Rate (DCR), Duration of Response (DOR), Overall Response Rate (ORR), Overall Survival (OS), Pharmacodynamic (PD) Profile of IOV-3001, Pharmacokinetics (PK) profile of IOV-3001, Progression-Free Survival (PFS)
Oncology